These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38543900)

  • 1. Toward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides.
    Petrovskis I; Skrastina D; Jansons J; Dislers A; Bogans J; Spunde K; Neprjakhina A; Zakova J; Zajakina A; Sominskaya I
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.
    Sominskaya I; Skrastina D; Dislers A; Vasiljev D; Mihailova M; Ose V; Dreilina D; Pumpens P
    Clin Vaccine Immunol; 2010 Jun; 17(6):1027-33. PubMed ID: 20410327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
    Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
    Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development.
    Zhao Y; Li Z; Voyer J; Li Y; Chen X
    ACS Appl Mater Interfaces; 2022 May; 14(19):21872-21885. PubMed ID: 35467839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
    Hassebroek AM; Sooryanarain H; Heffron CL; Hawks SA; LeRoith T; Cecere TE; Stone WB; Walter D; Mahsoub HM; Wang B; Tian D; Ivester HM; Allen IC; Auguste AJ; Duggal NK; Zhang C; Meng XJ
    J Med Virol; 2023 Feb; 95(2):e28503. PubMed ID: 36655751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
    Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
    Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate.
    Liu X; Chang X; Rothen D; Derveni M; Krenger P; Roongta S; Wright E; Vogel M; Tars K; Mohsen MO; Bachmann MF
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33921677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.
    Liu SJ; Leng CH; Lien SP; Chi HY; Huang CY; Lin CL; Lian WC; Chen CJ; Hsieh SL; Chong P
    Vaccine; 2006 Apr; 24(16):3100-8. PubMed ID: 16494977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.
    Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W
    Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.
    Zak AJ; Hoang T; Yee CM; Rizvi SM; Prabhu P; Wen F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.
    Pumpens P; Razanskas R; Pushko P; Renhof R; Gusars I; Skrastina D; Ose V; Borisova G; Sominskaya I; Petrovskis I; Jansons J; Sasnauskas K
    Intervirology; 2002; 45(1):24-32. PubMed ID: 11937768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis.
    Yin Y; Zhang J; Dong D; Liu S; Guo Q; Song X; Li G; Fu L; Xu J; Chen W
    Vaccine; 2008 Oct; 26(46):5814-21. PubMed ID: 18786589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.
    Sani MZ; Bargahi A; Momenzadeh N; Dehghani P; Moghadam MV; Maleki SJ; Nabipour I; Shirkani A; Akhtari J; Hesamizadeh K; Heidari S; Omrani F; Akbarzadeh S; Mohammadi M
    Appl Microbiol Biotechnol; 2021 Jan; 105(1):77-91. PubMed ID: 33215260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response.
    Long Q; Yang Y; Yang M; Bai H; Sun W; Yang X; Huang W; Li D; Ma Y
    Nanomedicine; 2022 Apr; 41():102527. PubMed ID: 35104670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Aβ antibodies induced by Aβ-HBc virus-like particles prevent Aβ aggregation and protect PC12 cells against toxicity of Aβ1-40.
    Feng G; Wang W; Qian Y; Jin H
    J Neurosci Methods; 2013 Aug; 218(1):48-54. PubMed ID: 23701997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system.
    Armero-Gimenez J; Wilbers R; Schots A; Williams C; Finnern R
    Front Immunol; 2023; 14():1088852. PubMed ID: 36776898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice.
    Sominskaya I; Skrastina D; Petrovskis I; Dishlers A; Berza I; Mihailova M; Jansons J; Akopjana I; Stahovska I; Dreilina D; Ose V; Pumpens P
    PLoS One; 2013; 8(9):e75938. PubMed ID: 24086668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.
    Schödel F; Moriarty AM; Peterson DL; Zheng JA; Hughes JL; Will H; Leturcq DJ; McGee JS; Milich DR
    J Virol; 1992 Jan; 66(1):106-14. PubMed ID: 1370083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.